A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis.

ABSTRACT: One-quarter of the world's population is infected with Mycobacterium tuberculosis (Mtb). After initial exposure, more immune-competent persons develop asymptomatic latent tuberculosis infection (LTBI) but not active diseases, creates an extensive reservoir at risk of developing active tuberculosis. Previously, we constructed a novel recombinant Sendai virus (SeV)-vectored vaccine encoding two dominant antigens of Mtb, which elicited immune protection against acute Mtb infection. In this study, nine Mtb latency-associated antigens were screened as potential supplementary vaccine candidate antigens, and three antigens (Rv2029c, Rv2028c, and Rv3126c) were selected based on their immune-therapeutic effect in mice, and their elevated immune responses in LTBI h

SUBMITTER: Hu Z 

PROVIDER: S-EPMC10769537 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature